Mount Sinai Named Official Medical Service Provider for International Sumo League
Mount Sinai Health SystemPhysicians from the Department of Rehabilitation and Human Performance will play a key role in preparing athletes for tournaments
Physicians from the Department of Rehabilitation and Human Performance will play a key role in preparing athletes for tournaments
High-risk pregnancy specialists from the Mount Sinai Health System are presenting research at the Annual Pregnancy Meeting of the Society for Maternal-Fetal Medicine (SMFM) from February 10-14
Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and others, have unveiled a detailed understanding of immune responses in cancer, marking a significant development in the field. The findings were published in the February 14 online issue of Cell. Utilizing data from more than 1,000 tumors across 10 different cancers, the study is the first to integrate DNA, RNA, and proteomics (the study of proteins), revealing the complex interplay of immune cells in tumors. The data came from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a program under the National Cancer Institute.
The Icahn School of Medicine at Mount Sinai announced today the appointment of David C. Thomas, MD, MS, MHPE, as Dean of Medical Education and Chair of the Department of Medical Education.
Study shows using advanced technology and time can prevent permanent vision loss
The Mount Sinai Recanati/Miller Transplantation Institute has received a $5 million gift from the Blavatnik Family Foundation, pledged across five years.
Mount Sinai research could lead to more consistency and safety measure.
Work will facilitate interdisciplinary study of feelings, emotions, moods, and other sensory experiences, as well as the development of treatments for mental disorders.
Machine-learning method aims to predict consequences of serious sleep disorder impacting millions in the U.S.
Findings shed light on mechanisms underlying psychosocial stress and depression susceptibility
Researchers at the Icahn School of Medicine at Mount Sinai have identified a new approach to controlling bacterial infections. The findings were described in the February 6 online issue of Nature Structural & Molecular Biology.
The Guyana Ministry of Health, the Mount Sinai Health System and Hess Corporation have announced the reopening and expansion of pathology and laboratory services at Georgetown Public Hospital Corporation to promote early diagnosis of diseases that will enhance patient care and treatment
The Windreich Department of Artificial Intelligence (AI) and Human Health at the Icahn School of Medicine at Mount Sinai announced a transformative $1.95 million gift from Schmidt Sciences to create The Eric and Wendy Schmidt AI in Human Health Fellowship Program.
New Research Center Aims to Deliver Breakthrough Advancements in Dermatology and Discover Solutions for Healthy and Allergic Skin
Mount Sinai Health System leaders will attend and present at Arab Health 2024, the Middle East’s largest healthcare exhibition and congress, on January 29 – February 1
Tisch Cancer Institute researchers discovered that a certain type of chemotherapy improves the immune system’s ability to fight off bladder cancer, particularly when combined with immunotherapy, according to a study published in Cell Reports Medicine in January.
The Icahn School of Medicine at Mount Sinai has been awarded a grant of more than $4 million from The Leona M. and Harry B. Helmsley Charitable Trust to support an innovative research project aimed at understanding the early stages of Crohn’s disease before noticeable symptoms develop.
Mount Sinai cardiologists warn about the risk of heart problems during winter for American Heart Month
New York, NY [January 4, 2023]—In a milestone study, researchers from the Icahn School of Medicine at Mount Sinai have harnessed the power of artificial intelligence (AI) to enhance the assessment of the heart’s right ventricle, which sends blood to the lungs.
Mount Sinai researchers have shown for the first time that a person’s beliefs related to drugs can influence their own brain activity and behavioral responses in a way comparable to the dose-dependent effects of pharmacology.
Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel “genetic priority score” (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score. The findings were described in the January 3 online issue of Nature Genetics [DOI: 10.1038/s41588-023-01609-2]. Studies have shown that drugs have an increased likelihood of success in clinical trials when the genes they target have been demonstrated to have genetic support. The new tool integrates multiple lines of genetic evidence to prioritize these drug targets.
Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric disorders. This discovery may pave the way for the development of improved medications targeting the same pathway. Their findings, detailed in the January 2 online issue of Nature Communications https://doi.org/10.1038/s41467-023-44601-4, show that a brain protein known as the TAAR1 receptor, a drug target known to regulate dopamine signaling in key reward pathways in the brain, differs significantly in humans compared to the preclinical rodent models on which drugs are typically tested. The study suggests considering species-specific differences in drug-receptor interactions and further investigation into ways asenapine affects the body, as steps toward potential therapeutic improvements.
A team of health equity researchers from several institutions has leveraged a complex web of data to test a hypothesis: That structural racism is associated with resources and structures at the neighborhood level that are closely associated with poor health.
Patient-specific mutation-engineered mouse reveals how sensory neurons may trigger some allergy conditions but block others, suggesting more precise design of JAK inhibitors is necessary.
Prestigious grant will allow the New York City Virus Hunters initiative to expand an ongoing collaboration with BioBus that enables young students to keep city safe and help avoid future pandemics.
In a novel study, researchers from the Icahn School of Medicine at Mount Sinai introduced LoGoFunc, an advanced computational tool that predicts pathogenic gain- and loss-of-function variants across the genome.
Rating measures quality, safety, and outcomes of the five most common heart procedures
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC). And in an early parallel study in humans, combining immunotherapy with dupilumab—an Interleukin-4 (IL-4) receptor-blocking antibody widely used for treating allergies and asthma—boosted patients' immune systems, with one out of the six experiencing significant tumor reduction. The findings were described in the December 6 issue of Nature.
Awarded $4 million in NIH grants to study new therapies for improved survival
A new analysis of the brain activity of people with post-traumatic stress disorder (PTSD) is the first to reveal that traumatic memories are represented in the brain in an entirely different way than sad autobiographical memories.
Rating measures quality, safety, and outcomes
The Icahn School of Medicine at Mount Sinai has been awarded a $3.2 million grant to support a free summer program for disadvantaged students interested in a career in medicine. The Health Resources and Services Administration, part of the U.S. Department of Health and Human Services, provided the five-year training grant.
Center aims to transform treatment and care for patients in Emergency Departments across the United States
A common concern about gender-affirming hormone therapy for transmasculine people is the risk of red blood cell volume changes and erythrocytosis, a high concentration of red blood cells, with the use of prescribed testosterone. However, Mount Sinai researchers have found that testosterone treatment may be safer than previously reported.
Could improve the health of millions of people and advance environmental justice for all
Nationally recognized leader in academic medicine, delivering high-quality health care as a physician, health policy researcher, and educator
The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.
Kimberly Glassman, PhD, RN, NEA-BC, FAONL, FAAN, has been appointed as the new Dean of the Mount Sinai Phillips School of Nursing.
Findings will help scientists understand how microgravity impacts the ability of human heart cells to withstand the stresses of space travel
Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different types of cancer. The study, published in Genome Research, serves as a comprehensive resource and lays the foundation for the development of next-generation cancer treatments and diagnostic markers.
Introducing the Allen Discovery Center for Neuroimmune Interactions at the Icahn School of Medicine at Mount Sinai, Co-Led by Weill Cornell Medicine
New 5-year contracts for the Mid-Hudson Valley and New York City region support continued clinical services, outreach, and education to injured and sick workers.
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening drastically improves its cure rate measured over a 20-year period, according to a large-scale international study by Mount Sinai researchers published in Radiology.